Overall survival favored abemaciclib plus fulvestrant after disease progression on prior CDK4/6i & endocrine therapy. Numerically longer mOS 32 m. vs 25 m. Updated PFS, PFS2 &a

MBC Advocate· @MBCadvocate · X·2026-10-24 20:27· 1 天前评分70

正文 · 原文

Overall survival favored abemaciclib plus fulvestrant after disease progression on prior CDK4/6i & endocrine therapy. Numerically longer mOS 32 m. vs 25 m. Updated PFS, PFS2 & chemo-free survival all favored abemaciclib plus fulvestrant. $AZN $LLY #ESMO26 https://mededgemea.com/new-cancer-treatment-data-to-be-presented-at-esmo-congress-2026/

51 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

1RO按 Rapid oral 1: Breast cancer, advanced stage 对上

Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy

https://esmocongress.esmo.org

4498PNCT03155997 NCT03155997 NCT03155997按 Translational research and biomarkers 对上

Association of p27 V109G SNP zygosity with outcomes and abemaciclib treatment effect in HR+, HER2– high-risk early breast cancer: Results from monarchE

https://esmocongress.esmo.org

来源：MBC Advocate · x.com